{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T02:07:39Z","timestamp":1782526059489,"version":"3.54.5"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1186\/s13054-021-03542-4","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T10:03:29Z","timestamp":1618221809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Iron Deficiency Defined by Hepcidin in Critically Ill Patients"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2484-6233","authenticated-orcid":false,"given":"Michele F.","family":"Eisenga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"key":"3542_CR1","doi-asserted-by":"publisher","unstructured":"Lasocki S, Asfar P, Jaber S, Ferrandiere M, Kerforne T, Asehnoune K, et al. Impact of treating iron deficiency, diagnosed according to hepcidin quantification, on outcomes after a prolonged ICU stay compared to standard care: A multicenter, randomized, single-blinded trial. Crit.Care. 2021;25:62. https:\/\/doi.org\/10.1186\/s13054-020-03430-3","DOI":"10.1186\/s13054-020-03430-3"},{"key":"3542_CR2","doi-asserted-by":"publisher","first-page":"e004519","DOI":"10.1161\/CIRCHEARTFAILURE.117.004519","volume":"11","author":"N Grote Beverborg","year":"2018","unstructured":"Grote Beverborg N, Klip IT, Meijers WC, Voors AA, Vegter EL, van der Wal HH, et al. Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients. Circ Heart Fail. 2018;11:e004519.","journal-title":"Circ Heart Fail"},{"key":"3542_CR3","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1182\/blood-2015-12-639112","volume":"127","author":"D Girelli","year":"2016","unstructured":"Girelli D, Nemeth E, Swinkels DW. Hepcidin in the diagnosis of iron disorders. Blood. 2016;127:2809\u201313.","journal-title":"Blood"},{"key":"3542_CR4","doi-asserted-by":"crossref","unstructured":"Vela D. Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker. Mol Med. 2018;24:5","DOI":"10.1186\/s10020-018-0008-7"},{"key":"3542_CR5","doi-asserted-by":"publisher","first-page":"E173","DOI":"10.1002\/ajh.24785","volume":"92","author":"MF Eisenga","year":"2017","unstructured":"Eisenga MF, Dullaart RPF, Berger SP, Touw DJ, Bakker SJL, Gaillard CAJM. Urinary prednisolone excretion is a determinant of serum hepcidin levels in renal transplant recipients. Am J Hematol. 2017;92:E173\u20135.","journal-title":"Am J Hematol"},{"issue":"3","key":"3542_CR6","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1097\/ALN.0b013e3182065c57","volume":"114","author":"S Lasocki","year":"2011","unstructured":"Lasocki S, Longrois D, Montravers P, Beaumont C. Hepcidin and anemia of the critically ill patient. Anesthesiology. 2011;114(3):688\u201394.","journal-title":"Anesthesiology"},{"issue":"6","key":"3542_CR7","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1007\/s00134-010-1794-8","volume":"36","author":"S Lasocki","year":"2010","unstructured":"Lasocki S, Baron G, Driss F, Westerman M, Puy H, Boutron I, Beaumont C, Montravers P. Diagnostic accuracy of serum hepcidin for iron deficiency in critically ill patients with anemia. Intensive Care Med. 2010;36(6):1044\u20138.","journal-title":"Intensive Care Med"},{"issue":"1","key":"3542_CR8","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s13054-018-2253-0","volume":"22","author":"S Lasocki","year":"2018","unstructured":"Lasocki S, Lefebvre T, Mayeur C, Puy H, Mebazaa A, Gayat E. group F-Is: Iron deficiency diagnosed using hepcidin on critical care discharge is an independent risk factor for death and poor quality of life at one year: an observational prospective study on 1161 patients. Crit Care. 2018;22(1):314.","journal-title":"Crit Care"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-021-03542-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-021-03542-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-021-03542-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T10:08:32Z","timestamp":1618222112000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-021-03542-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,12]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3542"],"URL":"https:\/\/doi.org\/10.1186\/s13054-021-03542-4","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,12]]},"assertion":[{"value":"19 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MFE received consulting and speaking fees from Vifor Pharma and served the Advisory Board of Cablon Medical.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"138"}}